Company is blamed for early halt of trial into obesity treatment
BMJ 2016; 352 doi: https://doi.org/10.1136/bmj.i1363 (Published 09 March 2016) Cite this as: BMJ 2016;352:i1363- Jacqui Wise
- London
Researchers have condemned companies that prematurely publicise study data, after a trial looking at the obesity treatment naltrexone-bupropion was stopped early before its cardiovascular safety could be fully established.
The US trial, published in JAMA,1 was stopped prematurely after the sponsor, Orexigen Therapeutics, released the interim data. The researchers said that, as a result, the cardiovascular safety of the treatment remained uncertain and that it would require evaluation in a new trial.
They said, “Premature release of interim data can result in inappropriate prejudgment about the benefits or risks of the studied therapy and make completion of the trial highly problematic.”
The …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.